Media headlines about Cyclacel Pharmaceuticals (NASDAQ:CYCC) have been trending positive recently, Accern reports. The research group identifies positive and negative news coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Cyclacel Pharmaceuticals earned a media sentiment score of 0.28 on Accern’s scale. Accern also assigned media headlines about the biotechnology company an impact score of 46.4386189722434 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
Here are some of the media headlines that may have effected Accern Sentiment Analysis’s analysis:
- Cyclacel Pharmaceuticals Inc (CYCC) Chaikin Money Flow in Positive Territory – Evergreen Caller (evergreencaller.com)
- Are There Any Catalysts to Propel Shares of Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC)? – FLBC News (flbcnews.com)
- Cyclacel Pharmaceuticals Inc (CYCC) Needle Moving 0.00% – Stock Press Daily (stockpressdaily.com)
- Turning Attention Towards Cyclacel Pharmaceuticals Inc (CYCC)’s Technicals – Sparta Review (spartareview.com)
- Aclaris Therapeutics, Inc. (ACRS) has a value of $24.60 per share While Cyclacel Pharmaceuticals, Inc. (CYCC) is … – Stocks Gallery (stocksgallery.com)
Shares of Cyclacel Pharmaceuticals (NASDAQ:CYCC) traded down 0.904% during midday trading on Tuesday, reaching $1.645. The company’s stock had a trading volume of 286,569 shares. The company has a 50-day moving average price of $1.73 and a 200-day moving average price of $3.82. Cyclacel Pharmaceuticals has a 12 month low of $1.56 and a 12 month high of $10.90.
Cyclacel Pharmaceuticals (NASDAQ:CYCC) last posted its quarterly earnings results on Wednesday, August 9th. The biotechnology company reported ($0.50) earnings per share for the quarter. Cyclacel Pharmaceuticals had a negative return on equity of 68.88% and a negative net margin of 1,128.13%. On average, equities research analysts predict that Cyclacel Pharmaceuticals will post ($2.25) earnings per share for the current fiscal year.
In related news, major shareholder Eastern Capital Ltd purchased 850,000 shares of the stock in a transaction on Wednesday, July 19th. The shares were purchased at an average price of $2.00 per share, with a total value of $1,700,000.00. Following the transaction, the insider now directly owns 2,167,261 shares of the company’s stock, valued at $4,334,522. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink. 4.00% of the stock is owned by insiders.
About Cyclacel Pharmaceuticals
Cyclacel Pharmaceuticals, Inc operates in the field of cell cycle biology. The Company has generated various families of anticancer drugs that act on the cell cycle, including nucleoside analogs, cyclin dependent kinase (CDK) inhibitors, polo-like kinase (PLK) inhibitors and Aurora Kinase/vascular endothelial growth factor receptor (AK/VEGFR) inhibitors.
Receive News & Ratings for Cyclacel Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyclacel Pharmaceuticals Inc. and related companies with our FREE daily email newsletter.